Table 1.

Patient characteristics and ABT-199 sensitivity for the primary acute myeloid leukemia patient samples

Patient	Gender	Age (year)	Disease	Disease status	FAB subtype	WBC (×103/μL)	Blast purity (%)	Cytogenetics	Fusion gene/ Gene mutation	ABT-199 IC50 (nM)
#1	Female	50	AML	At diagnosis	M4	22.66	52	46, XX, del(5q), add(12p)	dupMLL	23305
#2	Male	20	AML	At diagnosis	M2	23.55	42	45, X, -Y, t(8;21)(q22; q22)	AML1-ETO	30350
#3	Male	4	AML	At diagnosis	M3	4.71	75	46, XY, t(15;17)(q22; q21)	PML-RARα	1108
#4	Male	55	AML	At relapse	M2	5.64	14	46, XY, t(8;21)(q22; q22)	AML1-ETO	24320
#5	Female	57	AML	At relapse	M2	22.16	70	46, XX	FLT3 ITD	18795
#6	Male	60	AML	At diagnosis	M3	1.83	86	46, XY, t(15;17)(q22; q21)	PML-RARα	3443
#7	Female	53	AML	At relapse	M4	3.87	36	46, XX		21520
#8	Male	55	AML	At diagnosis	M2	17.71	32	46, XY		19395
#9	Female	35	AML	At relapse	M5	25.89	87	47, XX, +10, t(16;21)(p11; q22), add(11p)	TLS-ERG	23420
#10	Male	23	AML	At diagnosis	M2	25.12	53	46, XY, del(9q)		13000
#11	Female	43	AML	At diagnosis	M2	93.99	91	46, XX		12138
#12	Male	6	AML	At diagnosis	M3	1.65	85	46, XY, t(15;17)(q22; q21)	PML-RARα	3760
#13	Male	52	AML	At diagnosis	M2	8.84	27	46, XY, t(11;15;17)(q25; q15; q21)		14270
#14	Female	18	AML	At diagnosis	M3	1.62	64	46, XX		6021
#15	Female	63	AML	At diagnosis	M2	0.6	23	46, XX		17384
#16	Male	38	AML	At diagnosis	M3	2.27	90	46, XY, t(15;17)(q22; q21)	PML-RARα	1680